Ran Frenkel - Net Worth and Insider Trading

Ran Frenkel Net Worth

The estimated net worth of Ran Frenkel is at least $87,475 dollars as of 2024-11-13. Ran Frenkel is the EVP, Chief Dev. Officer of Karyopharm Therapeutics Inc and owns about 101,703 shares of Karyopharm Therapeutics Inc (KPTI) stock worth over $87,475. Details can be seen in Ran Frenkel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ran Frenkel has not made any transactions after 2022-02-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Ran Frenkel

To

Ran Frenkel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ran Frenkel owns 1 companies in total, including Karyopharm Therapeutics Inc (KPTI) .

Click here to see the complete history of Ran Frenkel’s form 4 insider trades.

Insider Ownership Summary of Ran Frenkel

Ticker Comapny Transaction Date Type of Owner
KPTI Karyopharm Therapeutics Inc 2022-02-17 EVP & WW Development Operations

Ran Frenkel Latest Holdings Summary

Ran Frenkel currently owns a total of 1 stock. Ran Frenkel owns 101,703 shares of Karyopharm Therapeutics Inc (KPTI) as of February 17, 2022, with a value of $87,475.

Latest Holdings of Ran Frenkel

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KPTI Karyopharm Therapeutics Inc 2022-02-17 101,703 0.86 87,475

Holding Weightings of Ran Frenkel


Ran Frenkel Form 4 Trading Tracker

According to the SEC Form 4 filings, Ran Frenkel has made a total of 6 transactions in Karyopharm Therapeutics Inc (KPTI) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Karyopharm Therapeutics Inc is the sale of 2,929 shares on February 17, 2022, which brought Ran Frenkel around $35,500.

Insider Trading History of Ran Frenkel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ran Frenkel Trading Performance

GuruFocus tracks the stock performance after each of Ran Frenkel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ran Frenkel is -17.04%. GuruFocus also compares Ran Frenkel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ran Frenkel within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ran Frenkel's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ran Frenkel

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -8.94 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -9.5 LIMIT LIMIT LIMIT LIMIT LIMIT

Ran Frenkel Ownership Network

Ownership Network List of Ran Frenkel

No Data

Ownership Network Relation of Ran Frenkel

Insider Network Chart

Ran Frenkel Owned Company Details

What does Karyopharm Therapeutics Inc do?

Who are the key executives at Karyopharm Therapeutics Inc?

Ran Frenkel is the EVP & WW Development Operations of Karyopharm Therapeutics Inc. Other key executives at Karyopharm Therapeutics Inc include director & President and CEO Richard A. Paulson , EVP & CFO & Treasurer Michael Mason , and SVP Sales & Commercial Ops Sohanya Roshan Cheng .

Karyopharm Therapeutics Inc (KPTI) Insider Trades Summary

Over the past 18 months, Ran Frenkel made no insider transaction in Karyopharm Therapeutics Inc (KPTI). Other recent insider transactions involving Karyopharm Therapeutics Inc (KPTI) include a net sale of 165,682 shares made by Richard A. Paulson , a net sale of 55,845 shares made by Michael Mason , and a net sale of 41,559 shares made by Sohanya Roshan Cheng .

In summary, during the past 3 months, insiders sold 27,326 shares of Karyopharm Therapeutics Inc (KPTI) in total and bought 0 shares, with a net sale of 27,326 shares. During the past 18 months, 2,078,182 shares of Karyopharm Therapeutics Inc (KPTI) were sold and 41,140 shares were bought by its insiders, resulting in a net sale of 2,037,042 shares.

Karyopharm Therapeutics Inc (KPTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Karyopharm Therapeutics Inc Insider Transactions

No Available Data

Ran Frenkel Mailing Address

Above is the net worth, insider trading, and ownership report for Ran Frenkel. You might contact Ran Frenkel via mailing address: C/o Karyopharm Therapeutics Inc., 85 Wells Avenue, 2nd Floor, Newton Ma 02459.